Familial Hypercholesterolaemia: An Updated Overall Management

Familial hypercholesterolaemia (FH), the commonest and serious but potentially treatable form of inherited dyslipidaemias, is characterised by severely elevated plasma low-density lipoprotein-cholesterol (LDL-C) level, which subsequently leads to premature coronary artery disease (pCAD). Effectivene...

Full description

Saved in:
Bibliographic Details
Main Authors: Mohd Kasim, Noor Alicezah (Author), An, Chua Yung (Author), Nawawi, Hapizah (Author)
Format: Book
Published: 2020-11-01.
Subjects:
Online Access:Link Metadata
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 repouitm_11223
042 |a dc 
100 1 0 |a Mohd Kasim, Noor Alicezah  |e author 
700 1 0 |a An, Chua Yung  |e author 
700 1 0 |a Nawawi, Hapizah  |e author 
245 0 0 |a Familial Hypercholesterolaemia: An Updated Overall Management 
260 |c 2020-11-01. 
500 |a https://ir.uitm.edu.my/id/eprint/11223/1/11223.pdf 
500 |a  Familial Hypercholesterolaemia: An Updated Overall Management. (2020) Journal of Clinical and Heatlh Sciences <https://ir.uitm.edu.my/view/publication/Journal_of_Clinical_and_Heatlh_Sciences/>, 5 (2). pp. 19-38. ISSN 0127-984X  
520 |a Familial hypercholesterolaemia (FH), the commonest and serious but potentially treatable form of inherited dyslipidaemias, is characterised by severely elevated plasma low-density lipoprotein-cholesterol (LDL-C) level, which subsequently leads to premature coronary artery disease (pCAD). Effectiveness of FH early detection and treatment is supported by the outcome of several international cohort studies. Optimal FH management relies on prescription of statins either alone or together with other lipid-lowering therapies (LLT). Intensive lifestyle intervention is required in parallel with LLT, which should be commenced at diagnosis in adults and childhood. Treatment with high intensity statin should be started as soon as possible. Combination with ezetimibe and/or bile acid sequestrants is indicated if target LDL-C is not achieved. For FH patients in the very-high risk category, if their LDL-C targets are not achieved, despite being on maximally tolerated statin dose and ezetimibe, proprotein convertase subtilisin/kexin type1 inhibitor (PCSK9i) is recommended. In statin intolerance, ezetimibe alone, or in combination with PCSK9i may be considered. Clinical evaluation of response to treatment and safety are recommended to be done about 4-6 weeks following initiation of treatment. Homozygous FH (HoFH) patients should be treated with maximally tolerated intensive LLT and, when available, with lipoprotein apheresis. This review highlights the overall management, and optimal treatment combinations in FH in adults and children, newer LLT including PCSK9i, microsomal transfer protein inhibitor, allele-specific oligonucleotide to ApoB100 and PCSK9 mRNA. Family cascade screening and/or screening of high-risk individuals, is the most cost-effective way of identifying FH cases and initiating early and adequate LLT. 
540 |a cc_by_4 
546 |a en 
690 |a RC Internal Medicine 
655 7 |a Article  |2 local 
655 7 |a PeerReviewed  |2 local 
787 0 |n https://ir.uitm.edu.my/id/eprint/11223/ 
787 0 |n https://jchs-medicine.uitm.edu.my/ 
787 0 |n https://doi.org/10.24191/jchs.v5i2.11121 
856 4 1 |u https://ir.uitm.edu.my/id/eprint/11223/  |z Link Metadata